Eylea® Injection for Wet AMD and DME

What Eylea Is and How It Works

Eylea® is an intravitreal anti-VEGF treatment for certain retinal diseases, including wet age-related macular degeneration and diabetic macular edema. It reduces abnormal blood vessel growth and fluid leakage in the macula. This page outlines how the therapy is used and how to access it with US shipping from Canada, including options for those paying without insurance.

CanadianInsulin.com is a prescription referral platform. We verify prescriptions with your prescriber when required, and licensed Canadian pharmacies dispense your order.

The active ingredient, aflibercept, is a recombinant fusion protein that binds VEGF-A, VEGF-B, and placental growth factor. By blocking these signals, it can reduce vascular permeability and macular swelling. The eylea dose schedule is set by the prescriber based on the labeled regimen. Injections are administered by retina specialists using aseptic technique with ocular anesthesia and antisepsis.

Who It’s For

This medicine is indicated for adults with neovascular (wet) age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and macular edema following branch or central retinal vein occlusion. Aflibercept 2 mg is not typically used in pediatric populations. It should not be used in patients with active ocular or periocular infections or active intraocular inflammation. Clinicians may exercise caution in patients with a history of arterial thromboembolic events.

For background on conditions it treats, see Age Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion.

Dosage and Usage

This therapy is a single-dose intravitreal injection into the affected eye. For neovascular AMD, common label guidance uses three monthly loading injections followed by maintenance dosing every eight weeks. For DME or diabetic retinopathy, initial monthly injections are typically followed by every-eight-week maintenance. For macular edema after retinal vein occlusion, monthly treatment is commonly used initially. The Eylea injection dose is delivered by a trained ophthalmic professional. Follow the FDA-approved label for condition-specific schedules.

Strengths and Forms

Availability may vary by pharmacy and timing. Common presentations include:

• Eylea 2 mg/0.05 mL single-use vial
• Single-use prefilled syringe containing aflibercept solution

Both presentations are intended for intravitreal use by healthcare professionals and are not for self-administration.

Missed Dose and Timing

If an injection visit is missed, the appointment is typically rescheduled as soon as practical. The exact plan depends on the treating condition and clinical assessment. Patients should not attempt to make up a dose on their own. Timing recommendations are the same whether the product is supplied as a vial or a prefilled syringe; this applies to Aflibercept injection 2 mg where listed on the label. Defer to the prescriber’s plan when re-starting or adjusting intervals.

Storage and Travel Basics

Store unopened product in the refrigerator according to the label, generally 2°C to 8°C. Keep in the original carton to protect from light. Do not freeze. Do not shake. If the package is supplied to bring to a clinic, you should keep it refrigerated and avoid temperature excursions during travel. Use an insulated container with cold packs and avoid placing the product directly on ice. Do not store in a car trunk or expose to direct heat. Keep out of reach of children.

For travel, carry the item in hand luggage with a copy of the prescription and a clinic letter if needed. Inspect the solution before the appointment; do not use if discolored or containing particulate matter. Follow all clinic-specific handling instructions upon arrival.

Benefits

By inhibiting VEGF signaling, this treatment can reduce macular edema and help stabilize or improve central vision in eligible patients. Regular dosing may lower fluid accumulation and decrease the need for rescue laser therapy. Clinic-based administration supports close monitoring of response and ocular pressure. Over time, some patients may maintain vision with less frequent maintenance intervals, per label and clinician judgment.

Side Effects and Safety

• Eye pain or discomfort
• Conjunctival hemorrhage
• Increased intraocular pressure shortly after injection
• Vitreous floaters
• Transient blurred vision
• Ocular irritation or pruritus
• Cataract progression

Serious but less common risks include endophthalmitis, retinal detachment or tear, intraocular inflammation, and arterial thromboembolic events such as stroke. Immediate evaluation is required for sudden vision changes, severe eye pain, increased redness, or light sensitivity. Hypersensitivity reactions can occur. Use is contraindicated in active intraocular infection or inflammation. The prescriber monitors intraocular pressure and fundus status after each injection.

Drug Interactions and Cautions

Systemic pharmacokinetic interactions are not typically expected because administration is intraocular and systemic exposure is low. However, combining multiple anti-VEGF agents is generally not recommended outside a clinician’s plan. Patients on antithrombotic therapy may have a higher likelihood of minor conjunctival bleeding at the injection site. Clinical judgment guides timing around ocular surgery or procedures. Report any history of stroke or myocardial infarction to the prescriber before treatment.

What to Expect Over Time

Initial monthly treatment often aims to reduce fluid and stabilize vision. After the loading phase, maintenance intervals are commonly extended according to the label and the individual clinical course. Some patients may require closer intervals if fluid recurs, while others may maintain control on less frequent visits. Regular follow-up imaging and exam findings guide ongoing scheduling. Adherence to planned appointments supports consistent outcomes.

Compare With Alternatives

Other anti-VEGF options may be considered depending on prior response, tolerability, and prescriber preference. Examples include Beovu® Pre Filled Syringe and Product Lucentis Prefilled Syringe. For additional background on a related agent, see the article Lucentis Uses Side Effects Dosage. Treatment choice remains individualized and should align with labeled indications and the prescriber’s assessment.

Pricing and Access

Many patients compare the Aflibercept 2 mg price across sources, including international mail-order services. With US shipping from Canada, you can review current pricing, request a quote, and upload a prescription during checkout. Cash-pay and self-pay requests are supported when a valid prescription is provided. For occasional offers, see Promotions. Secure, encrypted checkout protects submitted information.

Availability and Substitutions

Supply can vary by presentation or by pharmacy. If a specific vial or prefilled syringe is unavailable, the prescriber may recommend an alternative anti-VEGF option or adjust the follow-up plan based on clinical need. Substitutions require a valid prescription and clinical approval. This page reflects the standard formulation; other strengths or formats may have different directions and labeling.

Patient Suitability and Cost-Saving Tips

Candidates typically include adults with eligible retinal diagnoses who can attend clinic visits and tolerate intravitreal procedures. Patients with active ocular infection or inflammation should defer treatment until resolved. To help manage out-of-pocket costs, consider multi-pack ordering when feasible, align follow-up appointments for efficient use of supplies, and set up refill reminders in your account. Keeping documentation organized can streamline reorders and prescriber verification.

Questions to Ask Your Clinician

• Is this anti-VEGF appropriate for my diagnosis and eye exam findings?
• What loading and maintenance schedule do you recommend for my case?
• How will we monitor intraocular pressure and treatment response?
• What signs of complications should trigger immediate contact with the clinic?
• Could an alternative anti-VEGF be reasonable if response is limited?
• How will other eye procedures or surgeries affect the injection plan?
• What visit cadence do you expect after the loading phase?

Authoritative Sources

Eylea Prescribing Information (Regeneron)

FDA DailyMed

Health Canada Drug Product Database

You can start your request and upload your prescription today. We offer prompt, express, cold-chain shipping with US shipping from Canada. This information is educational and does not replace the advice of a healthcare professional; always follow the official label and your clinician’s guidance.